Considering the effects of STAP-1 on normal hematopoiesis, STAP-1 could represent an attractive therapeutic target for CML treatment by inhibiting STAT5 activity in CML LSCs. Here, STAT5A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.